Table 1:
Recent FDA approved therapies for FL.
| Drug | Approval Year | Mechanism/Target | Indication |
|---|---|---|---|
| Idelalisib | July 2014 | PI3K-delta inhibitor | Adults with RR-FL after ≥ 2 lines of systemic therapy. |
| Copanlisib | September 2017 | Pan-PI3K inhibitor | Adults with RR-FL after ≥ 2 lines of systemic therapy. |
| Duvelisib | September 2018 | PI3K-delta and gamma inhibitor | Adults with RR-FL after ≥ 2 lines of systemic therapy. |
| Lenalidomide with rituximab | May 2019 | Immunomodulatory; cereblon inhibitor | Adults with RR-FL |
| Tazemetostat | June 2020 | EZH2 inhibitor | 1. Adults with RR-FL after ≥ 2 lines of systemic therapy and have an EZH2 mutation 2. Adults with RR-FL without other treatment options |
| Umbralisib | February 2021 | PI3K-delta and CK1-epsilon inhibitor | Adults with RR-FL after ≥ 3 lines of systemic therapy. |
| Axicabtagene ciloleucel | March 2021 | Anti-CD19 CAR T-cell therapy | Adults with RR-FL after ≥ 2 lines of systemic therapy. |
CAR = chimeric antigen receptor, CK= casein kinase, PI3K = phosphoinositide 3-kinase, RR-FL = relapsed/refractory follicular lymphoma.